Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02332668 · ClinicalTrials.gov registry record · Phase 1

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

A Phase 1 study of Lymphoma and Melanoma, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
370
Enrollment target
17
Study locations

NCT02332668 is a Phase 1 study of Lymphoma and Melanoma that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 370 participants, below the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (23% lower). The trial reports 17 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02332668, a Phase 1 study of Lymphoma and Melanoma, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
370 participants
Enrollment target
17
Study locations

Study Summary

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrolment of participants with solid tumours and participants 6 months to under 12 years old with melanoma were closed. Enrolment of participants 12-18 years old with melanoma continues. Enrolment of participants who have tumours with specific traits (microsatellite-instability-high (MSI-H), and tumour-mutational burden-high ≥10 mutation/Mb (TMB-H)) also continues.

Conditions Studied

Lymphoma Melanoma Solid Tumor Classical Hodgkin Lymphoma Microsatellite-instability-high Solid Tumor

Interventions

  • BIOLOGICAL Pembrolizumab

Study Locations (17)

Other

  • MSD Brasil - São Paulo
  • MSD France - Paris
  • MSD Sharp & Dohme GmbH - München
  • Merck Sharp & Dohme Co. Ltd. - Hod HaSharon
  • MSD Italia S.r.l. - Rome
  • Merck Sharp & Dohme BV - Haarlem
  • Merck Sharp & Dohme Lda. - Paço de Arcos
  • MSD Korea LTD - Seoul
  • MSD Sweden - Stockholm
  • Merck Sharp & Dohme Ltd. - London

Colorado

  • Call for Information (Investigational Site 0019) - Aurora

Massachusetts

  • Call for Information (Investigational Site 0026) - Boston

New York

  • Call for Information (Investigational Site 0031) - New York

North Dakota

  • Call for Information (Investigational Site 0070) - Fargo

Ohio

  • Call for Information (Investigational Site 0032) - Cincinnati

South Dakota

  • Call for Information (Investigational Site 0071) - Sioux Falls

Texas

  • Call for Information (Investigational Site 0054) - Dallas

Trial Details

FieldValue
Enrollment Target 370 participants
Start Date 2015-03-18
Est. Completion 2027-10-25
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02332668

The ClinicalTrials.gov registry entry for NCT02332668 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (23% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.

NCT02332668 reports 17 study locations spanning 8 distinct geographic areas - top geographies include Other, Colorado, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02332668 about?

NCT02332668 is a clinical study titled "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)". Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back ...

What is the current status of trial NCT02332668?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 370 participants. The study started on 2015-03-18. Estimated completion is 2027-10-25.

What conditions does trial NCT02332668 study?

This clinical trial studies the following conditions: Lymphoma, Melanoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor.

What interventions are being tested in trial NCT02332668?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02332668?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02332668 being conducted?

This trial has 17 study locations across Colorado, Massachusetts, New York, North Dakota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Melanoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.